Evidence map›Paper›PMID 40799422›Full record

ArticleTranslational lung cancer research2025

Upfront osimertinib and as sequential therapy in patients with

Edouard Auclin, Pauline Du Rusquec, Victor Albarran-Artahona, Frank Aboubakar, Helena Gerber, Nicolas Epaillard, Gonzalo Recondo, Andrea De Giglio, Hugo Berthou, Juan Carlos Laguna and 12 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Translational lung cancer research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

22 authors.

Edouard AuclinDepartment of Medical Oncology, Hôpital Européen Georges Pompidou, AP-HP, Université Paris Cité, France.
Pauline Du RusquecThorax Institute Curie Montsouris, Institut Curie, Paris, France.
Victor Albarran-ArtahonaDepartment of Medical Oncology, Hospital Clinic de Barcelona, Barcelona, Spain.
Frank AboubakarUniversité de Louvain, Brussels, Belgium.
Helena GerberDepartment of Cancer Medicine, Institut Gustave Roussy, Villejuif, France.
Nicolas EpaillardDepartment of Oncology, Centre Hospitalier of French Polynesia, Pirae, Tahiti, French Polynesia.
Gonzalo RecondoDepartment of Medical Oncology, Center for Medical Education and Clinical Research (CEMIC), Buenos Aires, Argentina.
Andrea De GiglioDepartment of Medical and Surgical Sciences, University of Bologna, Bologna, Italy.
Hugo BerthouDepartment of Medical Oncology, Hôpital Européen Georges Pompidou, AP-HP, Université Paris Cité, France.
Juan Carlos LagunaDepartment of Medical Oncology, Hospital Clinic de Barcelona, Barcelona, Spain.
Teresa GorriaDepartment of Medical Oncology, Hospital Clinic de Barcelona, Barcelona, Spain.
Juan Bautista BlaquierDepartment of Medical Oncology, Center for Medical Education and Clinical Research (CEMIC), Buenos Aires, Argentina.
Beatriz Jimenez-MunarrizDepartment of Oncology, HM Hospitales, Madrid, Spain.
Marco TagliamentoDepartment of Oncology, IRCCS Ospedale Policlinico San Martino and University of Genova, Genova, Italy.
Alessandro Di FedericoDepartment of Medical and Surgical Sciences, University of Bologna, Bologna, Italy.
Gianluca SaccoDepartment of Oncology, IRCCS Ospedale Policlinico San Martino and University of Genova, Genova, Italy.
José MinattaDepartment of Medical Oncology, Center for Medical Education and Clinical Research (CEMIC), Buenos Aires, Argentina.
Nicolas GirardThorax Institute Curie Montsouris, Institut Curie, Paris, France.
Teresa Moran-BuenoDepartment of Medical Oncology, ICO de Badalona, Barcelona, Spain.
Rafael Lopez-CastroDepartment of Medical Oncology, Hospital Clinico Universitario de Valladolid, Valladolid, Spain.
Benjamin BesseDepartment of Cancer Medicine, Institut Gustave Roussy, Villejuif, France.
Laura MezquitaDepartment of Medical Oncology, Hospital Clinic de Barcelona, Barcelona, Spain.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Osimertinib is the preferred first-line (L1) treatment for epidermal growth factor receptor-mutant (m Methods: Retrospective multicenter study including consecutive patients with m Results: A total of 300 patients with m Conclusions: In this real-life study we showed that osimertinib upfront demonstrated prolonged PFS1

Indexed as

Epidermal growth factor receptor (EGFR)non-small cell lung cancer (NSCLC)osimertinibtyrosine kinase inhibitor (TKI)

Identifiers

PMID40799422
PMCPMC12337063

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.